During the afternoon session, Novartis AG moved 7.48%, compared to 0.12% for the S&P 500.
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is now trading -13.82% away from its average analyst target price of $104.25 per share. The 4 analysts following the stock have set target prices ranging from $102.0 to $107.0, and on average give Novartis AG a rating of buy.
Over the last year, NVS shares have gone down by -3.91%, which represents a difference of 9.3% when compared to the S&P 500. The stock's 52 week high is $90.33 per share and its 52 week low is $71.0. Based on Novartis AG's average gross margin growth of 1.46% over the last four years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Revenue (k) | Cost of Revenue (k) | Gross Margin | YoY Growth |
|---|---|---|---|---|
| 2022-12-31 | $51,828,000 | $15,486,000 | 70.12% | 0.19% |
| 2021-12-31 | $52,877,000 | $15,867,000 | 69.99% | 0.42% |
| 2020-12-31 | $49,898,000 | $15,121,000 | 69.7% | -0.95% |
| 2019-12-31 | $48,677,000 | $14,425,000 | 70.37% | 7.63% |
| 2018-12-31 | $53,166,000 | $18,407,000 | 65.38% | n/a |
